share_log

T2 Biosystems | 8-K: Agreement of Debt Conversion Into Equity

T2 Biosystems | 8-K: Agreement of Debt Conversion Into Equity

T2 Biosystems | 8-K：定期貸款轉股權協議
美股SEC公告 ·  04/19 04:17

Moomoo AI 已提取核心訊息

On April 12, 2024, T2 Biosystems, Inc., a Delaware-incorporated company, reported entering into a significant transaction involving the issuance of equity to settle outstanding loans. The company issued 3,280,618 shares of Common Stock and 17,160.48 shares of Series A Convertible Preferred Stock to a group of lenders led by CRG Partners III L.P. and its affiliates in exchange for the cancellation of $15.0 million in loans. This transaction was part of a Securities Purchase Agreement dated February 15, 2024. Concurrently, T2 Biosystems entered into a Consent and Amendment No. 10 to its Term Loan Agreement, which included the lenders' consent to the equity issuance and an extension of the interest payment period on the term loans. The shares issued in this transaction were not registered under the Securities Act of 1933, as the sale was made to accredited investors and relied on exemptions from registration requirements. Additionally, the company filed a Certificate of Designation with the State of Delaware, detailing the rights and preferences of the Series A Convertible Preferred Stock, including conversion rights, dividend entitlements, and liquidation participation.
On April 12, 2024, T2 Biosystems, Inc., a Delaware-incorporated company, reported entering into a significant transaction involving the issuance of equity to settle outstanding loans. The company issued 3,280,618 shares of Common Stock and 17,160.48 shares of Series A Convertible Preferred Stock to a group of lenders led by CRG Partners III L.P. and its affiliates in exchange for the cancellation of $15.0 million in loans. This transaction was part of a Securities Purchase Agreement dated February 15, 2024. Concurrently, T2 Biosystems entered into a Consent and Amendment No. 10 to its Term Loan Agreement, which included the lenders' consent to the equity issuance and an extension of the interest payment period on the term loans. The shares issued in this transaction were not registered under the Securities Act of 1933, as the sale was made to accredited investors and relied on exemptions from registration requirements. Additionally, the company filed a Certificate of Designation with the State of Delaware, detailing the rights and preferences of the Series A Convertible Preferred Stock, including conversion rights, dividend entitlements, and liquidation participation.
2024年4月12日，特拉華州註冊成立的公司T2 Biosystems, Inc. 報告說，已達成一項重大交易，涉及發行股權以結清未償貸款。該公司向由CRG Partners III L.P. 及其附屬公司牽頭的一組貸款機構發行了3,280,618股普通股和17,160.48股A系列可轉換優先股，以換取取消1,500萬美元的貸款。該交易是2024年2月15日證券購買協議的一部分。同時，T2 Biosystems簽署了其定期貸款協議的第10號同意和修正案，其中包括貸款人同意股票發行和延長定期貸款的利息支付期限。本次交易中發行的股票未根據1933年《證券法》進行註冊，因爲此次出售是向合格投資者進行的，並且依賴於註冊要求的豁免。此外，該公司還向特拉華州提交了指定證書，詳細說明了A系列可轉換優先股的權利和優先權，包括轉換權、股息權和清算參與權。
2024年4月12日，特拉華州註冊成立的公司T2 Biosystems, Inc. 報告說，已達成一項重大交易，涉及發行股權以結清未償貸款。該公司向由CRG Partners III L.P. 及其附屬公司牽頭的一組貸款機構發行了3,280,618股普通股和17,160.48股A系列可轉換優先股，以換取取消1,500萬美元的貸款。該交易是2024年2月15日證券購買協議的一部分。同時，T2 Biosystems簽署了其定期貸款協議的第10號同意和修正案，其中包括貸款人同意股票發行和延長定期貸款的利息支付期限。本次交易中發行的股票未根據1933年《證券法》進行註冊，因爲此次出售是向合格投資者進行的，並且依賴於註冊要求的豁免。此外，該公司還向特拉華州提交了指定證書，詳細說明了A系列可轉換優先股的權利和優先權，包括轉換權、股息權和清算參與權。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間